1
|
Pünnel LC, Lunter DJ. Development of a film-forming oleogel with increased substantivity for the treatment of psoriasis. Int J Pharm 2024; 659:124278. [PMID: 38806095 DOI: 10.1016/j.ijpharm.2024.124278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2024] [Revised: 05/21/2024] [Accepted: 05/24/2024] [Indexed: 05/30/2024]
Abstract
The aim of this work was the development of a film-forming formulation (FFF) for the topical treatment of psoriasis that shows an increased substantivity compared to conventional semi-solid dosage forms. The developed formulation is an oleogel. It is based on a combination of castor oil and medium chain triglycerides, and the oil-soluble film former MP-30 (Croda GmbH, Nettetal, Germany), a polyamide that upon mixing with a polar oil entraps the oil und thus substantially increases the viscosity of the formulation up to a semisolid state. Betamethasone dipropionate (BDP) and calcipotriole (CA) were used as active pharmaceutical ingredients (APIs). Oleogels of different compositions were evaluated regarding substantivity, rheological properties, ex-vivo penetration into the skin and ex-vivo permeation through the skin. Marketed products were used as controls. It was found that the amount of betamethasone dipropionate penetrating and permeating into and through the skin from the film-forming formulation is at an intermediate value compared to the marketed products. The substantivity of the developed formulation is described by an amount of 57.7 % formulation that remains on the skin surface and is thus significantly higher compared to the marketed products. In the film forming formulation, the proportion of API penetrating the skin remains the same when the skin repetitively brought in contact with a piece of textile during the penetration experiment. In contrast with the in-market formulations tested, this proportion was reduced by up to 97 %. As a result, the developed formulations can lead to an increased patient compliance.
Collapse
Affiliation(s)
- Larissa Carine Pünnel
- Department of Pharmaceutical Technology, Eberhard Karls University, Auf der Morgenstelle 8, 72076 Tübingen, Germany
| | - Dominique Jasmin Lunter
- Department of Pharmaceutical Technology, Eberhard Karls University, Auf der Morgenstelle 8, 72076 Tübingen, Germany.
| |
Collapse
|
2
|
Wang Y, Estee MM, Gan D, Lim YZ, Heritier S, Wluka AE, Hussain SM, Trevaskis NL, Cicuttini FM. Effect of 6-week treatment with topical betamethasone dipropionate in patients with symptomatic hand osteoarthritis: A randomized double-blind, placebo-controlled trial. OSTEOARTHRITIS AND CARTILAGE OPEN 2023; 5:100382. [PMID: 37426293 PMCID: PMC10329169 DOI: 10.1016/j.ocarto.2023.100382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Revised: 06/09/2023] [Accepted: 06/12/2023] [Indexed: 07/11/2023] Open
Abstract
Objective To examine the efficacy and safety of topical corticosteroid over 6 weeks in patients with symptomatic hand osteoarthritis. Design In a randomized, double-blind, placebo-controlled trial, community-based participants with hand osteoarthritis were randomly assigned (1:1) to topical Diprosone OV (betamethasone dipropionate 0.5 mg/g in optimised vehicle, n=54) or placebo (plain paraffin, n=52) ointment to painful joints 3 times daily for 6 weeks. Primary outcome was pain reduction [assessed by 100 mm visual analogue scale (VAS)] at 6 weeks. Secondary outcomes included changes in pain and function using the Australian Canadian Osteoarthritis Hand Index (AUSCAN), Functional Index for Hand Osteoarthritis (FIHOA), and Michigan Hand Outcomes Questionnaire (MHQ) at 6 weeks. Adverse events were recorded. Results Of 106 participants (mean age 64.2 years, 85.9% female), 103 (97.2%) completed the study. Change in VAS at 6 weeks was similar in the Diprosone OV and placebo groups (-19.9 vs. -20.9, adjusted difference 0.6, 95% CI -8.9 to 10.2). There were no significant between-group differences in change in AUSCAN pain [adjusted difference 25.8 (-16.0 to 67.5)], AUSCAN function [21.2 (-55.0 to 97.4)], FIHOA [-0.1 (-1.7 to 1.5)], or MHQ [-1.2 (-6.0 to 3.6)]. Incidence of adverse events was 16.7% in Diprosone OV and 19.2% in placebo group. Conclusions Topical Diprosone OV ointment, although well-tolerated, was no better than placebo in improving pain or function over 6 weeks in patient with symptomatic hand osteoarthritis. Future studies should consider examining joints with synovitis and whether delivery approaches enhancing transdermal penetration of corticosteroids into joints are effective in hand osteoarthritis. Trial registration ACTRN 12620000599976. Registered May 22, 2020.
Collapse
Affiliation(s)
- Yuanyuan Wang
- School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia
| | - Mahnuma Mahfuz Estee
- School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia
| | - Desmond Gan
- Department of Dermatology, Alfred Hospital, Melbourne, VIC 3004, Australia
| | - Yuan Z. Lim
- School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia
| | - Stephane Heritier
- School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia
| | - Anita E. Wluka
- School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia
| | - Sultana Monira Hussain
- School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia
| | - Natalie L. Trevaskis
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia
| | - Flavia M. Cicuttini
- School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia
| |
Collapse
|
3
|
Herbig ME, Evers DH, Gorissen S, Köllmer M. Rational Design of Topical Semi-Solid Dosage Forms-How Far Are We? Pharmaceutics 2023; 15:1822. [PMID: 37514009 PMCID: PMC10386014 DOI: 10.3390/pharmaceutics15071822] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2023] [Revised: 06/14/2023] [Accepted: 06/20/2023] [Indexed: 07/30/2023] Open
Abstract
Specific aspects of semi-solid dosage forms for topical application include the nature of the barrier to be overcome, aspects of susceptibility to physical and chemical instability, and a greater influence of sensory perception. Advances in understanding the driving forces of skin penetration as well as the design principles and inner structure of formulations, provide a good basis for the more rational design of such dosage forms, which still often follow more traditional design approaches. This review analyses the opportunities and constraints of rational formulation design approaches in the industrial development of new topical drugs. As the selection of drug candidates with favorable physicochemical properties increases the speed and probability of success, models for drug selection based on theoretical and experimental approaches are discussed. This paper reviews how progress in the scientific understanding of mechanisms and vehicle-influence of skin penetration can be used for rational formulation design. The characterization of semi-solid formulations is discussed with a special focus on modern rheological approaches and analytical methods for investigating and optimizing the chemical stability of active ingredients in consideration of applicable guidelines. In conclusion, the combination of a good understanding of scientific principles combined with early consideration of regulatory requirements for product quality are enablers for the successful development of innovative and robust semi-solid formulations for topical application.
Collapse
|
4
|
Park S. Biochemical, structural and physical changes in aging human skin, and their relationship. Biogerontology 2022; 23:275-288. [PMID: 35292918 DOI: 10.1007/s10522-022-09959-w] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Accepted: 02/25/2022] [Indexed: 11/02/2022]
Abstract
Skin is the largest organ of the human body, having the purpose of regulating temperature, protecting us from microbes or mechanical shocks, and allowing the sensations from touch. It is generally accepted that aging induces profound changes in the skin's biochemical, structural and physical properties, which can lead to impaired biological functions and/or diverse diseases. So far, the effects of aging on these skin properties have been well documented. However, very few studies have focused exclusively on the relationship among these critical properties in the aging process, which is this review's primary focus. Many in vivo, ex vivo, and in vitro techniques have been previously used to characterize these properties of the skin. This review aims to provide a comprehensive overview on the effects of aging on the changes in biochemical, structural, and physical properties, and explore the potential mechanisms of skin with the relation between these properties. First, we review different or contradictory results of aging-related changes in representative parameters of each property, including the interpretations of the findings. Next, we discuss the need for a standardized method to characterize aging-related changes in these properties, to improve the way of defining age-property relationship. Moreover, potential mechanisms based on the previous results are explored by linking the biochemical, structural, and physical properties. Finally, the need to study changes of various functional properties in the separate skin layers is addressed. This review can help understand the underlying mechanism of aging-related alterations, to improve the evaluation of the aging process and guide effective treatment strategies for aging-related diseases.
Collapse
Affiliation(s)
- Seungman Park
- Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, 21218, USA. .,Department of Mechanical Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA.
| |
Collapse
|
5
|
Sigg M, Daniels R. Impact of Alkanediols on Stratum Corneum Lipids and Triamcinolone Acetonide Skin Penetration. Pharmaceutics 2021; 13:pharmaceutics13091451. [PMID: 34575527 PMCID: PMC8469070 DOI: 10.3390/pharmaceutics13091451] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2021] [Revised: 08/18/2021] [Accepted: 09/08/2021] [Indexed: 11/23/2022] Open
Abstract
Alkanediols are widely used as multifunctional ingredients in dermal formulations. In addition to their preservative effect, considering their possible impact on drug penetration is also essential for their use. In the present study, the influence of 2-methyl-2,4-pentanediol, 1,2-pentanediol, 1,2-hexanediol and 1,2-octanediol on the skin penetration of triamcinolone acetonide from four different semisolid formulations was investigated. Furthermore, confocal Raman spectroscopy measurements were performed to examine the influence of the alkanediols on stratum corneum lipid content and order. Alkanediols were found to increase the penetration of triamcinolone acetonide. However, the extent depends strongly on the formulation used. In certain formulations, 1,2-pentanediol showed the highest effect, while in others the penetration-enhancing effect increased with the alkyl chain length of the alkanediol used. None of the tested alkanediols extracted lipids from the stratum corneum nor reduced its thickness. Notwithstanding the above, the longer-chained alkanediols cause the lipids to be converted to a more disordered state, which favors drug penetration. This behavior could not be detected for the shorter-chained alkanediols. Therefore, their penetration-enhancing effect is supposed to be related to an interaction with the hydrophilic regions of the stratum corneum.
Collapse
Affiliation(s)
| | - Rolf Daniels
- Correspondence: ; Tel.: +49-7071-297-2462; Fax: +49-7071-295-531
| |
Collapse
|
6
|
Mautz TT, Krapf JM, Goldstein AT. Topical Corticosteroids in the Treatment of Vulvar Lichen Sclerosus: A Review of Pharmacokinetics and Recommended Dosing Frequencies. Sex Med Rev 2021; 10:42-52. [PMID: 34226161 DOI: 10.1016/j.sxmr.2021.03.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Revised: 03/17/2021] [Accepted: 03/24/2021] [Indexed: 11/26/2022]
Abstract
Topical corticosteroids are often utilized as the first-line treatment for vulvar lichen sclerosus (VLS). However, there is wide variability in dosing regimens, as well as a lack of consensus on maintenance dosing. Available guidelines on dosing frequency and regimen continuation for VLS are based on clinical expert opinion and do not necessarily reflect the pharmacokinetics of topical corticosteroids. Over the past few decades, there have been many advances in the techniques used to measure the local and systemic absorption of topical corticosteroids. These techniques have led to a greater understanding of the pharmacokinetics and bioavailabilities of these medications. However, it is not clear how this new information has been applied in evaluating dosing regimens and commonly cited risks when considering short- and long-term use in different vulvar dermatoses. This purpose of this review is to evaluate the available evidence on pharmacokinetics, absorption rates, and concentration levels of topical corticosteroids in lesional and nonlesional skin. Additionally, the evidence regarding commonly cited risks of topical corticosteroid use, including dermal thinning, adrenal suppression, systemic immunosuppression, and tachyphylaxis are reviewed. Differences in the effects of topical corticosteroids on the varied tissues of the vulva are specifically explored. Finally, these considerations are applied to evaluate the current treatment guidelines for VLS to provide direction in determining an evidenced-based dosing regimen and to inform future research in this area. Mautz TT, Krapf JM, Goldstein AT. Topical Corticosteroids in the Treatment of Vulvar Lichen Sclerosus: A Review of Pharmacokinetics and Recommended Dosing Frequencies. Sex Med Rev 2021;XX:XXX-XXX.
Collapse
Affiliation(s)
| | - Jill M Krapf
- The Centers for Vulvovaginal Disorders, New York, NY, USA; The George Washington University School of Medicine and Health Sciences, Department of Obstetrics and Gynecology, Washington, DC, USA
| | - Andrew T Goldstein
- The Centers for Vulvovaginal Disorders, New York, NY, USA; The George Washington University School of Medicine and Health Sciences, Department of Obstetrics and Gynecology, Washington, DC, USA
| |
Collapse
|
7
|
Coderch L, Collini I, Carrer V, Barba C, Alonso C. Assessment of Finite and Infinite Dose In Vitro Experiments in Transdermal Drug Delivery. Pharmaceutics 2021; 13:pharmaceutics13030364. [PMID: 33801998 PMCID: PMC8000447 DOI: 10.3390/pharmaceutics13030364] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2021] [Revised: 02/19/2021] [Accepted: 03/06/2021] [Indexed: 12/31/2022] Open
Abstract
Penetration, usually with finite dosing, provides data about the total active amount in the skin and permeation, being the most used methodology, usually with infinite dosing, leads to data about pharmacokinetic parameters. The main objective of this work is to assess if results from permeation, most of them at finite dose, may be equivalent to those from penetration usually at infinite dose. The transdermal behavior of four drugs with different physicochemical properties (diclofenac sodium, ibuprofen, lidocaine, and caffeine) was studied using penetration/finite and kinetic permeation/infinite dose systems using vertical Franz diffusion cells to determine the relationships between permeation and penetration profiles. Good correlation of these two in vitro assays is difficult to find; the influence of their dosage and the proportion of different ionized/unionized compounds due to the pH of the skin layers was demonstrated. Finite and infinite dose regimens have different applications in transdermal delivery. Each approach presents its own advantages and challenges. Pharmaceutical industries are not always clear about the method and the dose to use to determine transdermal drug delivery. Being aware that this study presents results for four actives with different physicochemical properties, it can be concluded that the permeation/infinite results could not be always extrapolated to those of penetration/finite. Differences in hydrophilicity and ionization of drugs can significantly influence the lack of equivalence between the two methodologies. Further investigations in this field are still needed to study the correlation of the two methodologies and the main properties of the drugs that should be taken into account.
Collapse
|
8
|
Demurtas A, Pescina S, Nicoli S, Santi P, Ribeiro de Araujo D, Padula C. Validation of a HPLC-UV method for the quantification of budesonide in skin layers. J Chromatogr B Analyt Technol Biomed Life Sci 2021; 1164:122512. [PMID: 33454440 DOI: 10.1016/j.jchromb.2020.122512] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2020] [Revised: 12/14/2020] [Accepted: 12/18/2020] [Indexed: 12/19/2022]
Abstract
A simple and sensitive HPLC method for the quantification of budesonide in skin layers was developed and validated. Budesonide was extracted from stratum corneum, epidermis and dermis by means of a mixture of acetonitrile:water (recovery > 90%). Budesonide quantification was performed with a RP-C18 column using methanol and water mixture (69:31, v/v) as mobile phase, pumped at 0.8 ml/min. The absorbance was monitored at 254 nm. The method resulted to be selective, linear in the range 0.05-5 or 10 μg/ml, precise and accurate. LLOQ resulted to be 0.05 μg/ml. The developed method appeared to be appropriate for the quantification of budesonide in skin layers at the end of in vitro permeation experiments since the recovery of the applied dose was 97 ± 1%, in line with requirement of the OECD guideline for the testing of the chemicals (Skin absorption: in vitro method).
Collapse
Affiliation(s)
- Anna Demurtas
- Department of Food and Drug, University of Parma, Parco Area delle Scienze 27/a, 43124 Parma Italy
| | - Silvia Pescina
- Department of Food and Drug, University of Parma, Parco Area delle Scienze 27/a, 43124 Parma Italy
| | - Sara Nicoli
- Department of Food and Drug, University of Parma, Parco Area delle Scienze 27/a, 43124 Parma Italy
| | - Patrizia Santi
- Department of Food and Drug, University of Parma, Parco Area delle Scienze 27/a, 43124 Parma Italy
| | - Daniele Ribeiro de Araujo
- Human and Natural Sciences Centre, Federal University of ABC, Av dos Estados 5001, Bloco A, Torre 3, CEP 09210-580. Santo André, SP, Brazil
| | - Cristina Padula
- Department of Food and Drug, University of Parma, Parco Area delle Scienze 27/a, 43124 Parma Italy.
| |
Collapse
|
9
|
Gorzelanny C, Mess C, Schneider SW, Huck V, Brandner JM. Skin Barriers in Dermal Drug Delivery: Which Barriers Have to Be Overcome and How Can We Measure Them? Pharmaceutics 2020; 12:E684. [PMID: 32698388 PMCID: PMC7407329 DOI: 10.3390/pharmaceutics12070684] [Citation(s) in RCA: 78] [Impact Index Per Article: 19.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2020] [Revised: 07/11/2020] [Accepted: 07/14/2020] [Indexed: 12/13/2022] Open
Abstract
Although, drugs are required in the various skin compartments such as viable epidermis, dermis, or hair follicles, to efficiently treat skin diseases, drug delivery into and across the skin is still challenging. An improved understanding of skin barrier physiology is mandatory to optimize drug penetration and permeation. The various barriers of the skin have to be known in detail, which means methods are needed to measure their functionality and outside-in or inside-out passage of molecules through the various barriers. In this review, we summarize our current knowledge about mechanical barriers, i.e., stratum corneum and tight junctions, in interfollicular epidermis, hair follicles and glands. Furthermore, we discuss the barrier properties of the basement membrane and dermal blood vessels. Barrier alterations found in skin of patients with atopic dermatitis are described. Finally, we critically compare the up-to-date applicability of several physical, biochemical and microscopic methods such as transepidermal water loss, impedance spectroscopy, Raman spectroscopy, immunohistochemical stainings, optical coherence microscopy and multiphoton microscopy to distinctly address the different barriers and to measure permeation through these barriers in vitro and in vivo.
Collapse
Affiliation(s)
| | | | | | | | - Johanna M. Brandner
- Department of Dermatology and Venerology, Center for Internal Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; (C.G.); (C.M.); (S.W.S.); (V.H.)
| |
Collapse
|
10
|
Barros N, Kim H, Goudie MJ, Lee K, Bandaru P, Banton EA, Sarikhani E, Sun W, Zhang S, Cho HJ, Hartel MC, Ostrovidov S, Ahadian S, Hussain S, Ashammakhi N, Dokmeci MR, Herculano RD, Lee J, Khademhosseini A. Biofabrication of endothelial cell, dermal fibroblast, and multilayered keratinocyte layers for skin tissue engineering. Biofabrication 2020; 13. [PMID: 32650324 DOI: 10.1088/1758-5090/aba503] [Citation(s) in RCA: 41] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2020] [Accepted: 07/10/2020] [Indexed: 01/10/2023]
Abstract
The skin serves a substantial number of physiological purposes and is exposed to numerous biological and chemical agents owing to its large surface area and accessibility. Yet, current skin models are limited in emulating the multifaceted functions of skin tissues due to a lack of effort on the optimization of biomaterials and techniques at different skin layers for building skin frameworks. Here, we use biomaterial-based approaches and bioengineered techniques to develop a 3D skin model with layers of endothelial cell networks, dermal fibroblasts, and multilayered keratinocytes. Analysis of mechanical properties of gelatin methacryloyl (GelMA)-based bioinks mixed with different portions of alginate revealed bioprinted endothelium could be better modeled to optimize endothelial cell viability with a mixture of 7.5% GelMA and 2% alginate. Matrix stiffness plays a crucial role in modulating produced levels of Pro-Collagen I alpha-1 and matrix metalloproteinase-1 in human dermal fibroblasts and affecting their viability, proliferation, and spreading. Moreover, seeding human keratinocytes with gelatin-coating multiple times proves helpful in reducing culture time to create multilayered keratinocytes while maintaining their viability. The ability to fabricate selected biomaterials for each layer of skin tissues has implications in the biofabrication of skin systems for regenerative medicine and disease modeling.
Collapse
Affiliation(s)
- Natan Barros
- Center for Minimally Invasive Therapeutics (C-MIT), University of California - Los Angeles, Los Angeles, California, UNITED STATES
| | - Hanjun Kim
- University of California Los Angeles, Los Angeles, California, 90095, UNITED STATES
| | - Marcus J Goudie
- Center for Minimally Invasive Therapeutics (C-MIT), University of California - Los Angeles, Los Angeles, California, UNITED STATES
| | - KangJu Lee
- Bioengineering, UCLA, Los Angeles, California, UNITED STATES
| | - Praveen Bandaru
- Bioengineering, UCLA, Los Angeles, California, UNITED STATES
| | - Ethan A Banton
- Bioengineering, UCLA, Los Angeles, California, UNITED STATES
| | | | - Wujin Sun
- Bioengineering, UCLA, Los Angeles, California, UNITED STATES
| | - Shiming Zhang
- Bioengineering, UCLA, Los Angeles, California, UNITED STATES
| | - Hyun-Jong Cho
- Pharmacy, Kangwon National University, Chuncheon, Gangwon-do, Korea (the Republic of)
| | - Martin C Hartel
- Bioengineering, UCLA, Los Angeles, California, UNITED STATES
| | | | - Samad Ahadian
- Center for Minimally Invasive Therapeutics (C-MIT), University of California - Los Angeles, Los Angeles, California, UNITED STATES
| | - Saber Hussain
- , Molecular Bioeffects Branch, Wright Patterson AFB, Ohio, UNITED STATES
| | - Nureddin Ashammakhi
- Center for Minimally Invasive Therapeutics (C-MIT), University of California - Los Angeles, Los Angeles, California, UNITED STATES
| | - Mehmet R Dokmeci
- Radiology, UCLA, CNSI 4528, 570 Westwood Plaza, Los Angeles, California, 90095, UNITED STATES
| | | | - Junmin Lee
- Terasaki Institute, Los Angeles, California, UNITED STATES
| | - Ali Khademhosseini
- Center for Minimally Invasive Therapeutics, UCLA, Los Angeles, California, UNITED STATES
| |
Collapse
|
11
|
Carrer V, Alonso C, Pont M, Zanuy M, Córdoba M, Espinosa S, Barba C, Oliver MA, Martí M, Coderch L. Effect of propylene glycol on the skin penetration of drugs. Arch Dermatol Res 2019; 312:337-352. [PMID: 31786711 DOI: 10.1007/s00403-019-02017-5] [Citation(s) in RCA: 47] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2019] [Revised: 10/31/2019] [Accepted: 11/20/2019] [Indexed: 12/12/2022]
Abstract
Propylene glycol (PG) has been used in formulations as a co-solvent and/or to enhance drug permeation through the skin from topical preparations. Two skin in vitro permeation approaches are used to determine the effect of PG on drug penetration. The in vitro Skin-PAMPA was performed using 24 actives applied in aqueous buffer or PG. PG modulates permeability by increasing or diminishing it in the compounds with poor or high permeability, respectively. Percutaneous absorption using pigskin on Franz diffusion cells was performed on seven actives and their commercial formulations. The commercial formulations evaluated tend to have a lower permeability than their corresponding PG solutions but maintain the compound distribution in the different strata: stratum corneum, epidermis and dermis. The results indicate the enhancer properties of PG for all compounds, especially for the hydrophilic ones. Additionally, the Synchrotron-Based Fourier Transform Infrared microspectroscopy technique is applied to study the penetration of PG and the molecular changes that the vehicle may promote in the different skin layers. Results showed an increase of the areas under the curve indicating the higher amount of lipids in the deeper layers and altering the lipidic order of the bilayer structure to a more disordered lipid structure.
Collapse
Affiliation(s)
- Victor Carrer
- Institute of Advanced Chemistry of Catalonia-CSIC (IQAC-CSIC), Jordi Girona 18-26, 08034, Barcelona, Spain
| | - Cristina Alonso
- Institute of Advanced Chemistry of Catalonia-CSIC (IQAC-CSIC), Jordi Girona 18-26, 08034, Barcelona, Spain.
| | - Mercè Pont
- Almirall R&D Center, Ctra. Laureà Miró 408-410, 08980, Sant Feliu de Llobregat, Barcelona, Spain
| | - Miriam Zanuy
- Almirall R&D Center, Ctra. Laureà Miró 408-410, 08980, Sant Feliu de Llobregat, Barcelona, Spain
| | - Mònica Córdoba
- Almirall R&D Center, Ctra. Laureà Miró 408-410, 08980, Sant Feliu de Llobregat, Barcelona, Spain
| | - Sonia Espinosa
- Almirall R&D Center, Ctra. Laureà Miró 408-410, 08980, Sant Feliu de Llobregat, Barcelona, Spain
| | - Clara Barba
- Institute of Advanced Chemistry of Catalonia-CSIC (IQAC-CSIC), Jordi Girona 18-26, 08034, Barcelona, Spain
| | - Marc A Oliver
- Institute of Advanced Chemistry of Catalonia-CSIC (IQAC-CSIC), Jordi Girona 18-26, 08034, Barcelona, Spain
| | - Meritxell Martí
- Institute of Advanced Chemistry of Catalonia-CSIC (IQAC-CSIC), Jordi Girona 18-26, 08034, Barcelona, Spain
| | - Luisa Coderch
- Institute of Advanced Chemistry of Catalonia-CSIC (IQAC-CSIC), Jordi Girona 18-26, 08034, Barcelona, Spain
| |
Collapse
|